Last reviewed · How we verify
clopidogrel napadisilate + aspirin
This combination of clopidogrel napadisilate and aspirin inhibits platelet aggregation through dual antiplatelet pathways to prevent thrombotic events.
This combination of clopidogrel napadisilate and aspirin inhibits platelet aggregation through dual antiplatelet pathways to prevent thrombotic events. Used for Acute coronary syndrome, Prevention of stent thrombosis after percutaneous coronary intervention, Secondary prevention of cardiovascular events.
At a glance
| Generic name | clopidogrel napadisilate + aspirin |
|---|---|
| Sponsor | Seoul National University Hospital |
| Drug class | Dual antiplatelet agent |
| Target | P2Y12 receptor (clopidogrel); cyclooxygenase (aspirin) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Clopidogrel napadisilate is a prodrug that inhibits ADP-mediated platelet activation by blocking the P2Y12 receptor, while aspirin irreversibly inhibits cyclooxygenase (COX) to prevent thromboxane A2 synthesis. Together, they provide dual antiplatelet therapy targeting complementary pathways of platelet aggregation, reducing the risk of stent thrombosis and recurrent cardiovascular events.
Approved indications
- Acute coronary syndrome
- Prevention of stent thrombosis after percutaneous coronary intervention
- Secondary prevention of cardiovascular events
Common side effects
- Bleeding
- Dyspepsia
- Gastrointestinal hemorrhage
- Bruising
Key clinical trials
- The Effect and Safety of Combined Anti-platelet Treatment in Acute Ischemic Stroke Due to Large Artery Atherosclerosis (PHASE4)
- Short-Term Anticoagulation Versus Antiplatelet Therapy for Preventing Device Thrombosis Following Left Atrial Appendage Closure (PHASE4)
- Randomized Clinical Trial of Endovascular Recanalization for Symptomatic Non-Acute Intracranial Artery Occlusion（REPAIR） (NA)
- PFO Closure, Oral Anticoagulants or Antiplatelet Therapy After PFO-associated Stroke in Patients Aged 60 to 80 Years (PHASE3)
- Clopidogrel vs. Aspirin for Cardiovascular Risk Reduction in Patients With S. Aureus Bacteremia (PHASE4)
- Precision Reperfusion Therapy for Disabling Minor Stroke With Large Vessel Occlusion Beyond Time Window (PHASE3)
- SIMPLAAFY Clinical Trial (NA)
- INdobufen Versus asPirin in Endovascular Unruptured Intracranial Aneurysms Treatment (INPUT) (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: